New therapeutic targeting of Alzheimer’s disease with the potential use of proline-rich polypeptide complex to modulate an innate immune response - preliminary study

Table 2 Means and standard deviations (SD) of MMSE score in AD patients (n = 20) in relation to the innate immunity measured with PBLs resistance to viral infection (viral titer express in TCID₅₀) at t = 0. ANOVA linear contrast analysis was performed to investigate the relationship between the innate immunity of PBLs (range) and effect of PRP (left table) and MMSE score (right table). In addition, the mean of the innate immunity of PBLs at t = 0 (before PRP treatment) and t = 1 (after PRP treatment) and differences between t = 1 and t = 0 are shown

PBLs resistance/level of innate immunity				MMSE^**
Range t = 0	Mean t = 0	Mean t = 1	Mean difference	Mean	SD	n
0–1^*	0.13	1.13	1.00	21.00	1.83	4
2–2.5	2.25	2.00	− 0.25	18.50	4.73	4
3–3.5	3.07	1.50	− 1.57	18.14	3.72	7
4–4.5	4.10	2.10	− 2.00	14.40	2.79	5
F_contrast = 12.91, df = 1;16, p = 0.0024 r_{effect size} = 0.66 H₀: mean difference is the same in all groups H₁: linear relation between PRP effect and level of innate immunity				F_contrast = 7.67, df = 1;16, p = 0.0136 r_{effect size} = 0.56 H₀: mean MMSE is the same in all groups H₁: linear relation between mean MMSE and level of innate immunity

*PBLs with complete resistance to viral infection, high level of innate immunity
**Measured at the time of inclusion into the project
t = 0 before PRP treatment
t = 1 after PRP treatment

ISSN: 1742-2094